StoneChecker
Biotechnology - Radstock, England, United Kingdom
StoneChecker Employees
StoneChecker Details
StoneChecker Ltd is a health technology company focused on the development and commercialization of products to inform clinical management and to guide care for patients with kidney stones. The company is led by recognized experts in the field of clinical development and commercialization.More than 300 million patients worldwide suffer with kidney stones and the majority of these are working age adults. Despite these numbers relatively little funding is given to research and development in this field. StoneChecker Ltd aims to address this unmet clinical need by launching two novel products into the healthcare market during 2018. StoneChecker Ltd is wholly owned by Flying Brands plc; a publicly listed company on the London Stock Exchange.StoneChecker: Medical Imaging Software for Kidney Stones:StoneChecker is an innovative medical software designed to aid clinical decision making by providing personalised information about a patient's kidney stone. Physicians can apply the StoneChecker software to their patient's diagnostic CT scans to help decide which treatment will be most effective.StoneChecker Ltd has an exclusive worldwide licence to apply the TexRAD® algorithm (provided by TexRAD, part of Feedback Plc) to examine heterogeneity and ‘texture' not visible to the naked eye. Tested and validated at the University of Oxford, StoneChecker software will be available for research use in 2017 and commercially available in 2018.StonePrevent: Screening for the Causes of Kidney Stones:StonePrevent is a bespoke urine screening programme which aims to identify or exclude certain underlying causes of kidney stones. More than 300 million patients experience a kidney stone episode in their lifetime and as many as 50% have a recurrence. For some patients, there are reversible or addressable causes. After the diagnostic imaging tests and standard blood panel patients receive in hospital, it is recommended patients receive more extensive urine screening.Working closely with board-certified metabolic physicians who have designed a novel reporting system, StonePrevent will roll out a postal screening service with centralised laboratory facilities that can provide this complex medical service to healthcare services and directly to patients. Commercially available from 2018, StonePrevent will automate, centralise and simplify urine screening.
